GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anebulo Pharmaceuticals Inc (FRA:214) » Definitions » 3-Year EBITDA Growth Rate

Anebulo Pharmaceuticals (FRA:214) 3-Year EBITDA Growth Rate : 0.00% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Anebulo Pharmaceuticals 3-Year EBITDA Growth Rate?

Anebulo Pharmaceuticals's EBITDA per Share for the three months ended in Mar. 2024 was €-0.06.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Competitive Comparison of Anebulo Pharmaceuticals's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Anebulo Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anebulo Pharmaceuticals's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anebulo Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Anebulo Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.



Anebulo Pharmaceuticals 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.


Anebulo Pharmaceuticals  (FRA:214) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.


Anebulo Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Anebulo Pharmaceuticals's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Anebulo Pharmaceuticals (FRA:214) Business Description

Traded in Other Exchanges
Address
1017 Ranch Road 620 South, Suite 107, Lakeway, TX, USA, 78734
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company. It is developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.

Anebulo Pharmaceuticals (FRA:214) Headlines

No Headlines